Condition: End Stage Renal Disease (ESRD) · CKD 5D, Hemodialysis · CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder · Sponsor: Mansoura University
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
This description comes directly from the study's public registry record.
Basma M. Sayed Ahmed, M.Sc. · +201207753307 · basma_mohamed@mans.edu.eg
Always discuss trial participation with your own doctor first.
| Urology and Nephrology Center | Al Mansurah, Please Select, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06906874